Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling

Brain

Volumn 133, Issue 2, 2010, Pages 375-388

  Hu, Wei ^a   Nessler, Stefan ^b,c,d   Hemmer, Bernhard ^c   Eagar, Todd N ^a,e   Kane, Lawrence P ^f   Leliveld, S Rutger ^b   Müller Schiffmann, Andreas ^b   Gocke, Anne R ^a   Lovett Racke, Amy ^g   Ben, Li Hong ^a   Hussain, Rehana Z ^a   Breil, Andreas ^a   Elliott, Jeffrey L ^a   Puttaparthi, Krishna ^a   Cravens, Petra D ^a   Singh, Mahendra P ^a   Petsch, Benjamin ^h   Stitz, Lothar ^h   Racke, Michael K ^g   Korth, Carsten ^b   Stüve, Olaf ^a,b,e,i   more..

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

ⁱ VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Immunosuppression; Prion; Small interfering RNA; T cell signaling

Indexed keywords

PRION PROTEIN; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL DISRUPTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LYMPHOID CELL; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; DEMYELINATING AUTOIMMUNE DISEASES, CNS; FEMALE; GENE SILENCING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PRIONS; RECEPTORS, ANTIGEN, T-CELL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 77249104004     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp298     Document Type: Article

References (30)

1. Antoine N, Cesbron JY, Coumans B, Jolois O, Zorzi W, Heinen E. Differential expression of cellular prion protein on human blood and tonsil lymphocytes. Haematologica 2000; 85: 475-480
2. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992; 356: 577-582
3. Burthem J, Urban B, Pain A, Roberts DJ. The normal cellular prion protein is strongly expressed by myeloid dendritic cells. Blood 2001; 98: 3733-3738
4. Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak RJ, Bolton DC, et al. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 1990; 61: 185-192
5. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992; 71: 649-662
6. Chatila T, Silverman L, Miller R, Geha R. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol 1989; 143: 1283-1289
7. de Souza AJ, Oriss TB, O'malley KJ, Ray A, Kane LP. T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc Natl Acad Sci USA 2005; 102: 17113-17118
8. c glycoform heterogeneity as a function of brain region: implications for selective targeting of neurons by prion strains. J Neuropathol Exp Neurol 1999; 58: 1000-1009
9. Durig J, Giese A, Schulz-Schaeffer W, Rosenthal C, Schmucker U, Bieschke J, et al. Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br J Haematol 2000; 108: 488-495
10. Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 1996; 15: 1255-1264
11. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993; 72: 551-560
12. Ingram RJ, Isaacs JD, Kaur G, Lowther DE, Reynolds CJ, Boyton RJ, et al. A role of cellular prion protein in programming T-cell cytokine responses in disease. FASEB J 2009; 23: 1672-1684
13. Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2001; 2: 37-44.
14. Kane LP, Mollenauer MN, Weiss A. A proline-rich motif in the C terminus of Akt contributes to its localization in the immunological synapse. J Immunol 2004; 172: 5441-5449
15. Kaye J, Porcelli S, Tite J, Jones B, Janeway CA Jr. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J Exp Med 1983; 158: 836-856
16. Krebs B, Dorner-Ciossek C, Schmalzbauer R, Vassallo N, Herms J, Kretzschmar HA. Prion protein induced signaling cascades in monocytes. Biochem Biophys Res Commun 2006; 340: 13-22.
17. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994; 78: 399-408.
18. Li R, Liu D, Zanusso G, Liu T, Fayen JD, Huang JH, et al. The expression and potential function of cellular prion protein in human lymphocytes. Cell Immunol 2001; 207: 49-58.
19. Liu WS, Heckman CA. The sevenfold way of PKC regulation. Cell Signal 1998; 10: 529-542
20. Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, et al. Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004; 21: 719-731
21. Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol 1994; 8: 121-127
22. Mattei V, Garofalo T, Misasi R, Circella A, Manganelli V, Lucania G, et al. Prion protein is a component of the multimolecular signaling complex involved in T cell activation. FEBS Lett 2004; 560: 14-18.
23. Muller-Schiffmann A, Petsch B, Leliveld SR, Muyrers J, Salwierz A, Mangels C, et al. Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity. Mol Immunol 2009; 46: 532-540
24. Puttaparthi K, Wojcik C, Rajendran B, DeMartino GN, Elliott JL. Aggregate formation in the spinal cord of mutant SOD1 transgenic mice is reversible and mediated by proteasomes. J Neurochem 2003; 87: 851-860
25. Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, et al. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol 2002; 169: 6720-6732
26. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006; 116: 1037-1044
27. Testi R, Phillips JH, Lanier LL. Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C. J Immunol 1989; 142: 1854-1860.
28. Tsutsui S, Hahn JN, Johnson TA, Ali Z, Jirik FR. Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis. Am J Pathol 2008; 173: 1029-1041
29. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
30. Zabel M, Greenwood C, Thackray AM, Pulford B, Rens W, Bujdoso R. Perturbation of T-cell development by insertional mutation of a PrP transgene. Immunology 2009; 127: 226-236